Leidos awarded DTRA contract for research and development of WMD solutions
The contract is a multiple-award indefinite delivery/indefinite quantity contract with a five-year performance base period and an option for an additional five years, valued at $4 billion for all awardees if all possible options are utilized. The contract award is a subsidiary to the Combating Weapons of Mass Destruction Research and Technology Development ID/IQ contract.
Leidos specializes in health, engineering and national security solutions. It is one of seven contract awardees to compete for task orders and will be responsible for research and development of technology to solve scientific and technological challenges the Department of Defense faces in the realms of non-proliferation, consequence management and counter-proliferation.
"Leidos is proud to provide continued support of the mission of the Defense Threat Reduction Agency to safeguard our nation and develop technologies to defeat weapons of mass destruction," Leidos Group President John Fratamico said.
The DTRA is the Combat Support Agency to the DoD for non-proliferation and weapons of mass destruction. The DTRA is responsible for addressing all threats that encompass weapons of mass destruction, including chemical, biological, radiological, nuclear and high yield explosives, to protect the nation against these threats.